HeartSciences Inc. 8-K

What Happened
HeartSciences Inc. filed an 8-K on June 26, 2026 (Items 5.02 and 9.01) disclosing the grant of an equity award to Andrew Simpson and an associated amendment to his employment agreement. The company states the offering and issuance of the "Equity Award" will be exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, based in part on representations of the company’s officers and directors. The related documents are dated June 22, 2026.

Key Details

• Person involved: Andrew Simpson (employment amendment and restricted stock award).
• Documents filed/furnished: Amendment No. 1 to Employment Agreement (dated June 22, 2026) and Notice of Grant and Restricted Stock Award Agreement (dated June 22, 2026) (listed in Item 9.01).
• Securities law treatment: Company asserts exemption from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D and applicable state laws.
• Filing date of the Form 8-K: June 26, 2026.

Why It Matters
Equity awards and employment amendments for executives can affect insider incentives and potentially dilute existing shareholders depending on the grant size and vesting. HeartSciences’ reliance on private-placement exemptions means the award wasn’t registered with the SEC; the exact economic terms (number of shares, vesting, exercise price, if any) are detailed in the filed exhibits. Investors should review the June 22, 2026 exhibits for full terms to assess potential dilution and implications for executive retention.